Align Technology, Inc.
ALGNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAlign Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The $10.98B market capitalization puts ALGN squarely in large-cap range for its industry. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth.
Market Cap
$10.98B
Beta
1.67
P/E (TTM)
26.87
P/E (Fwd)
12.46
EPS (TTM)
$5.75
EPS (Fwd)
$12.40
ROE
10.2%
ROA
7.6%
Cash
$1.10B
Total Debt
$120.8M
Free CF
$594.1M
52W Change
13.9%
Annual Financials
Cash vs Debt
Where ALGN stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, ALGN finished 16.55% below its 150-day moving average ($168.27) and 17.28% below its 200-day moving average ($169.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALGN overbought or oversold?
At the October 13, 2026 close, ALGN's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Align Technology, Inc. holds $1.10B in cash against $120.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $594.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 10.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $3.73B (2022) to $4.03B (2025).
Align Technology, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing ALGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.